Phase 3Not yet recruiting
Semaglutide in Alcohol Use Disorder
A 45-week, Randomized, Controlled Trial of Semaglutide on Alcohol Related Outcomes in Adults With Alcohol Use Disorder and Obesity
- Sponsor
- University of Minnesota (Academic or other)
- Enrollment
- 128 planned
- Conditions
- Alcohol Use Disorder (AUD); Obesity
- Interventions
- Wegovy; Placebo
- Ages
- adults, older adults
- Registry
- NCT07949474
Full record on ClinicalTrials.gov
From the registry
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.
Primary outcomes
- Heavy drinking days
- Total drinking days
History
Study completion expected
Primary completion expected
Expected to start
Registered